|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.47 HKD | +0.22% |
|
+5.18% | -2.61% |
| Apr. 23 | Portugal's Fidelidade says it decided not to move forward with Luz Saude's IPO | RE |
| Apr. 23 | Fosun International Unit Logs 236 Million Euro in 2023 Profit | MT |
HONG KONG (Reuters) - Shares in Shanghai Henlius Biotech, backed by Chinese conglomerate Fosun International, were set to open down 4% at HK$47.45 ($6.05) on their market debut in Hong Kong on Wednesday.
Henlius last week priced its initial public offering (IPO) in Hong Kong at the low end of an indicative price range of HK$49.6 to HK$57.8 per share, raising $410 million.
The IPO launched on Sept. 11 was seen as a test for investor appetite amid political unrest that has engulfed the Chinese-ruled territory for nearly four months and has weighed on its stock market.
(Reporting by Julie Zhu and Sumeet Chatterjee; Editing by Clarence Fernandez)
| 1st Jan change | Capi. | |
|---|---|---|
| -2.61% | 4.62B | |
| -6.67% | 113B | |
| -4.37% | 87.84B | |
| +20.96% | 64.04B | |
| +3.41% | 61.27B | |
| +9.86% | 43.34B | |
| +8.18% | 41.12B | |
| +17.43% | 34.17B | |
| +1.06% | 24.84B | |
| -5.38% | 22.4B |
FOSUN INTERNATIONAL LIMITED 
